Rituximab-treated patients with rheumatic disease had diminished antibody levels and impaired CD8+ T-cell responses after SARS-CoV-2 infection and vaccination, though CD4+ responses remained intact.
Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.
JAK inhibitor therapy targets inflammation and correlates with improvements in carotid artery measurements, while baseline vascular markers continue to predict cardiovascular risk.
A recent study reveals significant treatment response improvements in severe psoriatic arthritis and extensive psoriasis, emphasizing the need for personalized treatment strategies and sensitive outcome measures. (Source: Psoriatic Arthritis Research Consortium)